SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD
TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world's largest randomised controlled trial of a Sirolimus-coated balloon for Peripheral Artery Disease (SirPAD) at the ACC 2026 Scientific Sessions. The primary results of the...
DNV SELECTED TO CERTIFY CLASS D DEVICES FOR LEADING U.S. MANUFACTURER UNDER EU IVDR
DNV supports the manufacturer's transition to new regulation with its digital certification platform and transparent, predictable project management. OSLO, Norway, March 31, 2026 /PRNewswire/ -- DNV, a designated Notified Body for the European Union's In Vitro Diagnostic Regulation (IVDR) and Medical Device Regulation (MDR), has been selected by a leading U.S. diagnostics...
Abbisko Therapeutics’ FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children
SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-molecule FGFR2/3 inhibitor, for the treatment of children with achondroplasia (ACH)....
Amorepacific, Viol Medical Sign MOU on Beauty and Medical Devices
SEOUL, South Korea, March 31, 2026 /PRNewswire/ -- Amorepacific announced on March 27 that it has signed a memorandum of understanding (MOU) with Viol Medical, an energy‑based medical device company, to collaborate in the beauty and medical device sectors. The collaboration aligns with Amorepacific's long‑term strategy to provide holistic beauty solutions that connect...
AIA launches ProsperLife Insurance Plan: Lifelong protection for every stage of life
Premiums from only HKD 60 per day for an HKD 1.9 million sum assured HONG KONG, March 31, 2026 /PRNewswire/ -- AIA Hong Kong & Macau announces the launch of the ProsperLife Insurance Plan, a participating whole life insurance plan designed to support customers and their families' life protection needs through every stage of life, from starting a family...
NAVER D2SF Makes Follow-On Investment in Nuvilab, AI Nutrition Analytics Startup
SEONGNAM, South Korea, March 31, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Nuvilab, an AI-powered nutrition analytics healthcare startup. Following its seed investment shortly after the company's founding in 2021, NAVER D2SF has participated again in Nuvilab's Series A bridge round, recognizing its strong growth potential in the...
NAVER D2SF Makes Follow-On Investment in Soundable Health, an AI-Driven Health Tech Startup Scaling in the U.S. Market
SEOUL, South Korea, March 31, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Soundable Health, a health tech startup leveraging AI-powered acoustic analysis to enable clinical-grade diagnostics through everyday devices. Having participated in Soundable Health's seed round in 2019, NAVER D2SF joined this Pre-Series A round, citing the company's...
Innovent’s Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics advancing OLN324 into...
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has...
Sanyou Milestone | Recognized as a “Shanghai Municipal Enterprise Technology Center,” Further Validating for Innovation Excellence
SHANGHAI, March 30, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals has recently been honored as a "Shanghai Municipal Enterprise Technology Center" in recognition of its outstanding technological innovation capabilities, comprehensive R&D infrastructure, sustained investment in innovation, and remarkable achievements in technology commercialization. This designation marks a higher level of authoritative recognition for Sanyou's research and development capabilities, innovation mechanisms, and industry...
